{"title":"巨噬细胞CBX4通过其SUMO E3连接酶活性增强动脉粥样硬化。","authors":"Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo","doi":"10.1007/s10557-025-07724-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.</p><p><strong>Methods: </strong>We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.</p><p><strong>Results: </strong>CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE<sup>-/-</sup> mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.</p><p><strong>Conclusions: </strong>Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity.\",\"authors\":\"Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo\",\"doi\":\"10.1007/s10557-025-07724-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.</p><p><strong>Methods: </strong>We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.</p><p><strong>Results: </strong>CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE<sup>-/-</sup> mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.</p><p><strong>Conclusions: </strong>Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.</p>\",\"PeriodicalId\":9557,\"journal\":{\"name\":\"Cardiovascular Drugs and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Drugs and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10557-025-07724-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07724-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity.
Purpose: Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.
Methods: We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE-/-) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.
Results: CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE-/- mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.
Conclusions: Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.
期刊介绍:
Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.
Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.
Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.